Table 6. Adjusted odds ratio (AOR) and 95% confidence intervals (CI) of clinical statuses associated with genotypic frequencies of IL-18 -607A/C and IL-18-137 G/C in oral cancer patients (n=567).
|
Clinical Stage
| ||||
|---|---|---|---|---|
| IL-18 -607 | Stage < III (n=248) (%) | Stage ≥ III (n=319) (%) | AOR (95% CI) | p value |
| CC | 63 (25.4%) | 77 (24.1%) | 1.00 | |
| AC | 120 (48.4%) | 142 (44.5%) | 0.95 (0.62-1.44) | p=0.81 |
| AA | 65 (26.2%) | 100 (31.4%) | 1.25 (0.78-1.98) | p=0.34 |
| IL-18 -137 | Stage < III (n=248) (%) | Stage ≥ III (n=319) (%) | AOR (95% CI) | p value |
| GG | 180 (72.6%) | 257 (80.6%) | 1.00 | |
| GC | 67 (27.0%) | 55 (17.2%) | 0.59 (0.39-0.89) | p=0.01 |
| CC | 1 (0.4%) | 7 (2.2%) | 4.58 (0.55-37.66) | p=0.15 |
| Tumor size | ||||
| IL-18 -607 | ≤ T2 (n=348) (%) | > T2 (n=219) (%) | AOR (95% CI) | p value |
| CC | 90 (25.9%) | 50 (22.8%) | 1.00 | |
| AC | 166 (47.7%) | 96 (43.9%) | 1.02 (0.66-1.57) | p=0.92 |
| AA | 92 (26.4%) | 73 (33.3%) | 1.40 (0.88-2.24) | p=0.14 |
| IL-18 -137 | ≤ T2 (n=348) (%) | > T2 (n=219) (%) | AOR (95% CI) | P value |
| GG | 257 (73.8%) | 180 (82.2%) | 1.00 | |
| GC | 88 (25.3%) | 34 (15.5%) | 0.56 (0.35-0.87) | p=0.01 |
| CC | 3 (0.9%) | 5 (2.3%) | 2.30 (0.54-9.81) | p=0.25 |
| Lymph node metastasis | ||||
| IL-18 -607 | No (n=357) (%) | Yes (n=210) (%) | AOR (95% CI) | p value |
| CC | 85 (23.8%) | 55 (26.2%) | 1.00 | |
| AC | 172 (48.2%) | 90 (42.9%) | 0.80 (0.52-1.23) | p=0.31 |
| AA | 100 (28.0%) | 65 (30.9%) | 1.00 (0.63-1.60) | p=0.97 |
| IL-18 -137 | No (n=357) (%) | Yes (n=210) (%) | AOR (95% CI) | P value |
| GG | 261 (73.1%) | 176 (83.8%) | 1.00 | |
| GC | 91 (25.5%) | 31 (14.8%) | 0.51 (0.32-0.80) | p=0.003 |
| CC | 5 (1.4%) | 3 (1.4%) | 0.85 (0.20-3.65) | p=0.83 |
| Distant metastasis | ||||
| IL-18 -607 | No (n=559) (%) | Yes (n=8) (%) | AOR (95% CI) | p value |
| CC | 137 (24.5%) | 3 (37.5%) | 1.00 | |
| AC | 259 (46.3%) | 3 (37.5%) | 0.43 (0.08-2.27) | p=0.32 |
| AA | 163 (29.2%) | 2 (25%) | 0.49 (0.08-3.08) | p=0.45 |
| IL-18 -137 | No (n=559) (%) | Yes (n=8) (%) | AOR (95% CI) | P value |
| GG | 429 (76.8%) | 8 (100%) | 1.00 | |
| GC | 122 (21.8%) | 0 (0%) | ─ | p=0.94 |
| CC | 8 (1.4%) | 0 (0%) | ─ | p=0.98 |
| Cell differentiated grade | ||||
| IL-18 -607 | ≦Grade I (n=75) (%) | Grade I (n=492) (%) | AOR (95% CI) | p value |
| CC | 19 (25.3%) | 121 (24.6%) | 1.00 | |
| AC | 39 (52.0%) | 223 (45.3%) | 0.89 (0.49-1.63) | p=0.72 |
| AA | 17 (22.7%) | 148 (30.1%) | 1.37 (0.68-2.77) | p=0.37 |
| IL-18 -137 | ≦Grade I (n=75) (%) | Grade I (n=492) (%) | AOR (95% CI) | p value |
| GG | 61 (81.3%) | 376 (76.4%) | 1.00 | |
| GC | 14 (18.7%) | 108 (22.0%) | 1.24 (0.66-2.32) | p=0.48 |
| CC | 0 | 8 (1.6%) | ─ | p=0.98 |
The odds ratios (ORs) with their 95% confidence intervals (CIs) were estimated by logistic regression models.
The adjusted odds ratios (AORs) with their 95% confidence intervals (CIs) were estimated by multiple logistic regression models, after controlling for gender, age, alcohol, tobacco, and areca consumption.
> T2: multiple tumor more than 2 cm. Cell differentiate grade: grade I: well differentiated; grade II: moderately differentiated; grade III: poorly differentiated.